Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling

PLoS Genetics

Volumn 12, Issue 8, 2016, Pages

  Shen, Hua ^a,b   Yu, Xiaobo ^c   Yang, Fengming ^a,b   Zhang, Zhihua ^d   Shen, Jianxin ^d   Sun, Jin ^a   Choksi, Swati ^e   Jitkaew, Siriporn ^f   Shu, Yongqian ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d HEBEI NORTH UNIVERSITY   (China)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 206; MICRORNA 31; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VASCULOTROPIN A; CCL2 PROTEIN, HUMAN; FOXO3 PROTEIN, HUMAN; MIRN1 MICRORNA, HUMAN; MIRN206 MICRORNA, HUMAN; MIRN31 MICRORNA, HUMAN; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

CANCER-ASSOCIATED FIBROBLASTS; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; CHEMOKINE CCL2; FORKHEAD BOX PROTEIN O3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84984918737     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006244     Document Type: Article

References (53)

1. Kalluri R, Zeisberg M, Fibroblasts in cancer. Nature reviews Cancer. 2006;6(5):392–401. doi: 10.1038/nrc187716572188.
2. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA, Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature reviews Molecular cell biology. 2002;3(5):349–63. doi: 10.1038/nrm80911988769.
3. Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, et al. A stromal address code defined by fibroblasts. Trends in immunology. 2005;26(3):150–6. doi: 10.1016/j.it.2004.11.01415745857; PubMed Central PMCID: PMC3121558.
4. Mueller MM, Fusenig NE, Friends or foes—bipolar effects of the tumour stroma in cancer. Nature reviews Cancer. 2004;4(11):839–49. doi: 10.1038/nrc147715516957.
5. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48. doi: 10.1016/j.cell.2005.02.03415882617.
6. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999;5(5):1041–56. 10353737.
7. Elenbaas B, Weinberg RA, Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Experimental cell research. 2001;264(1):169–84. doi: 10.1006/excr.2000.513311237532.
8. Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, Becker V, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney international. 2000;57(4):1521–38. doi: 10.1046/j.1523-1755.2000.00997.x10760088.
9. Ambros V, microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–6. 11779458.
10. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, et al. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 2013;32(27):3246–53. doi: 10.1038/onc.2012.35122890324; PubMed Central PMCID: PMC3711253.
11. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer discovery. 2012;2(12):1100–8. doi: 10.1158/2159-8290.CD-12-020623171795; PubMed Central PMCID: PMC3685866.
12. Yang TS, Yang XH, Chen X, Wang XD, Hua J, Zhou DL, et al. MicroRNA-106b in cancer-associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN. FEBS letters. 2014;588(13):2162–9. doi: 10.1016/j.febslet.2014.04.05024842611.
13. Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell death & disease. 2013;4:e684. doi: 10.1038/cddis.2013.21323788041; PubMed Central PMCID: PMC3702298.
14. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63. doi: 10.1038/nature0618817914389.
15. Li X, Xu Q, Wu Y, Li J, Tang D, Han L, et al. A CCL2/ROS autoregulation loop is critical for cancer-associated fibroblasts-enhanced tumor growth of oral squamous cell carcinoma. Carcinogenesis. 2014;35(6):1362–70. doi: 10.1093/carcin/bgu04624531940.
16. Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P, Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2015. doi: 10.1038/onc.2015.13225961921.
17. Ostuni R, Kratochvill F, Murray PJ, Natoli G, Macrophages and cancer: from mechanisms to therapeutic implications. Trends in immunology. 2015;36(4):229–39. doi: 10.1016/j.it.2015.02.00425770924.
18. O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. The American journal of pathology. 2010;176(3):1241–55. doi: 10.2353/ajpath.2010.09073520110414; PubMed Central PMCID: PMC2832146.
19. Bhowmick NA, Neilson EG, Moses HL, Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–7. doi: 10.1038/nature0309615549095; PubMed Central PMCID: PMC3050735.
20. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(14):4966–71. doi: 10.1073/pnas.040106410115051869; PubMed Central PMCID: PMC387357.
21. Folkman J, Watson K, Ingber D, Hanahan D, Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339(6219):58–61. doi: 10.1038/339058a02469964.
22. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. The American journal of pathology. 2005;166(3):675–84. doi: 10.1016/S0002-9440(10)62289-415743780; PubMed Central PMCID: PMC1780139.
23. Strieter RM, Wiggins R, Phan SH, Wharram BL, Showell HJ, Remick DG, et al. Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. Biochemical and biophysical research communications. 1989;162(2):694–700. 2787988.
24. Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer research. 2012;72(11):2768–79. doi: 10.1158/0008-5472.CAN-11-356722472119; PubMed Central PMCID: PMC3367125.
25. Dey P, Strom A, Gustafsson JA, Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene. 2014;33(33):4213–25. doi: 10.1038/onc.2013.38424077289.
26. Stahlhut C, Suarez Y, Lu J, Mishima Y, Giraldez AJ, miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. Development. 2012;139(23):4356–64. doi: 10.1242/dev.08377423132244; PubMed Central PMCID: PMC3509730.
27. Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho KK, Zwolinska AK, et al. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 2012;31(14):1845–58. doi: 10.1038/onc.2011.36821860419; PubMed Central PMCID: PMC3232453.
28. Callegari E, Gramantieri L, Domenicali M, D'Abundo L, Sabbioni S, Negrini M, MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell death and differentiation. 2015;22(1):46–57. doi: 10.1038/cdd.2014.13625190143; PubMed Central PMCID: PMC4262781.
29. Sharkey RM, Goldenberg DM, Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA: a cancer journal for clinicians. 2006;56(4):226–43. 16870998.
30. Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, et al. The role of miRNA in inflammation and autoimmunity. Autoimmunity reviews. 2013;12(12):1160–5. doi: 10.1016/j.autrev.2013.07.00323860189.
31. Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K, et al. Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene. 2014;33(1):97–107. doi: 10.1038/onc.2012.53623208491.
32. Martinez-Outschoorn UE, Lisanti MP, Sotgia F, Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Seminars in cancer biology. 2014;25:47–60. doi: 10.1016/j.semcancer.2014.01.00524486645.
33. Luga V, Wrana JL, Tumor-stroma interaction: Revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer research. 2013;73(23):6843–7. doi: 10.1158/0008-5472.CAN-13-179124265274.
34. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer research. 2002;62(4):1093–102. 11861388.
35. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR, A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer research. 2003;63(23):8360–5. 14678997.
36. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S, et al. GPER mediates activation of HIF1alpha/VEGF signaling by estrogens. Cancer research. 2014;74(15):4053–64. doi: 10.1158/0008-5472.CAN-13-359024894716.
37. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G, Tumor and its microenvironment: a synergistic interplay. Seminars in cancer biology. 2013;23(6 Pt B):522–32. doi: 10.1016/j.semcancer.2013.08.00724012661.
38. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer cell. 2009;15(1):21–34. doi: 10.1016/j.ccr.2008.12.00419111878.
39. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, et al. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer research. 2013;73(13):3842–51. doi: 10.1158/0008-5472.CAN-12-197423704211; PubMed Central PMCID: PMC3702636.
40. Quail DF, Joyce JA, Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37. doi: 10.1038/nm.339424202395; PubMed Central PMCID: PMCPMC3954707.
41. Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N, Yoshihara M, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(21):7629–36. doi: 10.1158/1078-0432.CCR-05-079816278381.
42. Lewis C, Murdoch C, Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. The American journal of pathology. 2005;167(3):627–35. 16127144; PubMed Central PMCID: PMCPMC1698733.
43. Webb AE, Brunet A, FOXO transcription factors: key regulators of cellular quality control. Trends in biochemical sciences. 2014;39(4):159–69. doi: 10.1016/j.tibs.2014.02.00324630600; PubMed Central PMCID: PMC4021867.
44. Lam EW, Brosens JJ, Gomes AR, Koo CY, Forkhead box proteins: tuning forks for transcriptional harmony. Nature reviews Cancer. 2013;13(7):482–95. doi: 10.1038/nrc353923792361.
45. McCabe N, Hanna C, Walker SM, Gonda D, Li J, Wikstrom K, et al. Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM. Cancer research. 2015;75(11):2159–65. doi: 10.1158/0008-5472.CAN-14-350225870146.
46. Wen Y, Grandis JR, Emerging drugs for head and neck cancer. Expert opinion on emerging drugs. 2015;20(2):313–29. doi: 10.1517/14728214.2015.103165325826749.
47. Bertoli G, Cava C, Castiglioni I, MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics. 2015;5(10):1122–43. doi: 10.7150/thno.1154326199650; PubMed Central PMCID: PMC4508501.
48. van Rooij E, Kauppinen S, Development of microRNA therapeutics is coming of age. EMBO molecular medicine. 2014;6(7):851–64. doi: 10.15252/emmm.20110089924935956; PubMed Central PMCID: PMC4119351.
49. Iorio MV, Croce CM, MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine. 2012;4(3):143–59. doi: 10.1002/emmm.20110020922351564; PubMed Central PMCID: PMC3376845.
50. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer. 2013;109(3):641–50. doi: 10.1038/bjc.2013.36923846169; PubMed Central PMCID: PMCPMC3738112.
51. Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B, Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PLoS One. 2013;8(11):e81408. doi: 10.1371/journal.pone.008140824282590; PubMed Central PMCID: PMCPMC3839880.
52. Wang R, Chen XF, Shu YQ, Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics. American journal of cancer research. 2015;5(1):32–51. 25628919; PubMed Central PMCID: PMC4300719.
53. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012;40(2):761–74. doi: 10.1093/nar/gkr73021917858; PubMed Central PMCID: PMCPMC3258133.